Edition:
India

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

5,886JPY
18 Jul 2019
Change (% chg)

¥-109 (-1.82%)
Prev Close
¥5,995
Open
¥6,020
Day's High
¥6,024
Day's Low
¥5,864
Volume
960,100
Avg. Vol
1,114,509
52-wk High
¥11,490
52-wk Low
¥5,864

Select another date:

Fri, Mar 22 2019

Photo

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

Nikkei falls as financials drag; Eisai indicated to dive

TOKYO, March 22 Japan's Nikkei fell in choppy trade on Friday as financial stocks languished, reflecting more cautious U.S. monetary policy, while the drug sector tumbled after Eisai and Biogen said they will end their Alzheimer's drug trials.

Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trials

TOKYO Eisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orders after the Japanese drugmaker and its partner Biogen Inc said they are ending two drug trials of their experimental Alzheimer's disease drug aducanumab.

Biogen, Eisai scrap Alzheimer drug trials

March 21 Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.

Select another date: